June 23rd 2021
The FDA approved Pradaxa (dabigatran etexilate) to treat venous thromboembolism in children aged 3 months to less than 12 years.
Influenza Prevention in the At-Risk Adult Population and the Pharmacist’s Role in an Evolving Influenza Vaccine Landscape
View More
Utilizing Targeted Agents for Treatment of HFrEF: The Role of the Pharmacist in Medication Selection and Therapy Management
1.0 Credit / Cardiology
View More
Expert Insight on Advances in the Therapeutic Landscape of Hypertrophic Cardiomyopathy
1 Credit / Cardiology
View More
Redefining Optimal Therapy for Patients with Heart Failure with Reduced Ejection Fraction: Integrating New Guidelines, Emerging Agents, and Pharmacist-led Transitions of Care
1.5 Credits / Cardiology
View More
The Impact of PCSK9 Modulation on Cardiovascular Outcomes: Recent Advances and the Managed Care Implications
1.5 Credits / Cardiology
View More
Targeting the Clinical Course of Hypertrophic Cardiomyopathy: Keeping a Beat on New and Emerging Therapies
2.0 Credits / Cardiology
View More
The Management of HFrEF With New and Emerging Mechanisms of Action: Updates for Pharmacists
1.5 Credits / Cardiology
View More
Recent Advances in Omega-3 Fatty Acids to Reduce Risk of ASCVD in Patients With Elevated Triglyceride Levels
0.75 Credit / Cardiology
View More
Introduction to Anticoagulation and the Appropriate Patient
1.0 Credit / Cardiology
View More
The Treatment Landscape and a Review of Approved DOAC Agents
1.0 Credit / Cardiology
View More
The Role of the Pharmacist in Optimizing DOAC Utilization Across Practice Settings
1.0 Credit / Cardiology
View More
Understanding the Challenges of Homozygous Familial Hypercholesterolemia
1.0 Credit / Cardiology
View More
Navigating the Therapeutic Landscape of Homozygous Familial Hypercholesterolemia
1.0 Credit / Cardiology
View More
Maximizing Patient Outcomes Through Pharmacist-Led Homozygous Familial Hypercholesterolemia Management
1.0 Credit / Cardiology
View More